Key Highlights
- Eli Lilly’s investigational triple-receptor drug retatrutide successfully completed its inaugural Phase 3 trial in Type 2 diabetes
- The drug reduced HbA1c levels by 1.7%–2% compared to 0.8% with placebo over 40 weeks
- Body weight decreased by as much as 16.8% among participants receiving the top dose
- The medication activates GLP-1, GIP, and glucagon receptors—exceeding the dual- or single-receptor approach of current therapies
- FDA submission remains pending; Lilly anticipates seven additional Phase 3 results before 2025 concludes
Eli Lilly revealed Thursday that its experimental compound retatrutide successfully achieved primary endpoints in its first Phase 3 diabetes study, demonstrating significant reductions in blood glucose alongside substantial weight reduction in individuals with Type 2 diabetes.
The 40-week clinical investigation enrolled Type 2 diabetes patients who were controlling their condition solely through lifestyle modifications—diet and physical activity. Participants began the study with baseline HbA1c measurements ranging from 7% to 9.5%.
Across various dosing regimens, retatrutide achieved average HbA1c reductions between 1.7% and 2%, significantly surpassing the 0.8% decrease observed in the placebo group. This outcome satisfied the study’s primary efficacy measure.
Regarding body composition changes, participants receiving the maximum dose experienced an average weight reduction of 16.8% among those who completed treatment. Using an intent-to-treat analysis that included all randomized participants regardless of completion status, weight loss averaged 15.3%.
By comparison, Lilly’s commercially available medication Zepbound produced weight reductions ranging from 11% to 13.1% in diabetes patients during similar 40-week studies. While retatrutide’s results appear superior, direct comparative trials have not been conducted.
Scotiabank’s Louise Chen characterized the findings as “the highest levels of weight loss we’ve seen from an obesity drug to date” within a patient population notorious for difficulty losing weight.
Analysts at J.P. Morgan presented a more cautious interpretation, highlighting that the drug’s efficacy gains must be weighed against elevated adverse event rates relative to Lilly’s diabetes medication Mounjaro.
Mechanism of Action Behind Retatrutide
Retatrutide is administered as a weekly subcutaneous injection that stimulates three distinct hormone pathways—GLP-1, GIP, and glucagon receptors—hence its informal designation as a “triple-G” agonist. This represents one additional target compared to Zepbound (tirzepatide), which engages GLP-1 and GIP, and two more than Novo Nordisk‘s Wegovy (semaglutide), which activates only GLP-1.
The therapeutic rationale involves simultaneously reducing appetite, stabilizing glucose levels, and enhancing metabolic rate through this multi-receptor engagement.
Adverse events were predominantly gastrointestinal in nature. Approximately 26.5% of top-dose recipients reported nausea, 22.8% experienced diarrhea, and 17.6% had vomiting episodes. Treatment discontinuation due to tolerability issues occurred in up to 5% of participants, which Lilly characterized as comparatively modest.
A limited subset of patients developed dysesthesia—an abnormal or uncomfortable nerve sensation.
Regulatory Timeline and Next Steps
Lilly has not yet submitted regulatory applications for retatrutide approval in either obesity or diabetes indications. Thursday’s announcement represents only the second Phase 3 data release for this investigational compound.
The pharmaceutical company anticipates data from seven more Phase 3 studies throughout 2025, encompassing diverse patient demographics and clinical scenarios.
Separately, Lilly is preparing to introduce its oral obesity medication orforglipron during the second quarter of this year, contingent upon FDA clearance.
Meanwhile, Novo Nordisk is advancing competitive efforts. In March 2025, Novo acquired rights to a triple-receptor compound from United Laboratories International through a transaction valued at up to $2 billion—though this candidate remains in early-stage development with commercialization several years distant.
Shares of Eli Lilly (LLY) edged lower in premarket trading Thursday following the clinical data release.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
